Compare · GIA vs LIVN
GIA vs LIVN
Side-by-side comparison of GigCapital 5 Inc. (GIA) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GIA and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.31B, about 14.7x GIA ($292.5M).
- LIVN has hit the wire 4 times in the past 4 weeks while GIA has been quiet.
- LIVN has more recent analyst coverage (20 ratings vs 0 for GIA).
- Company
- GigCapital 5 Inc.
- LivaNova PLC
- Price
- $3.62-13.81%
- $78.25+0.08%
- Market cap
- $292.5M
- $4.31B
- 1M return
- -
- -3.21%
- 1Y return
- -
- +39.25%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 20
GigCapital 5 Inc.
GigCapital5, Inc. is a blank check company. The company was incorporated in 2021 and is based in Palo Alto, California.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest GIA
- Catalyze Partners Appoints Raanan Horowitz to Board of Advisors
- SEC Form 8-K filed by GigCapital 5 Inc.
- SEC Form SC 13D filed by GigCapital 5 Inc.
- SEC Form SC 13D filed by GigCapital 5 Inc.
- GigCapital 5 Inc. filed SEC Form 8-K: Other Events
- SEC Form 3 filed by new insider Budagov Stas
- SEC Form 3 filed by new insider Weiner Zeev
- SEC Form 3 filed by new insider Dickson Daniel
- SEC Form 3 filed by new insider Taylor Ross
- GigCapital 5 Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Latest LIVN
- Director Story Brooke sold $187,270 worth of Ordinary Shares (2,300 units at $81.42), decreasing direct ownership by 23% to 7,488 units (SEC Form 4)
- LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
- Director Bianchi Francesco sold $131,538 worth of Ordinary Shares (1,650 units at $79.72), decreasing direct ownership by 17% to 7,934 units (SEC Form 4)
- SEC Form 3 filed by new insider Liddy Anne M.
- Chief Innovation Officer Tezel Ahmet exercised 12,692 units of Ordinary Shares at a strike of $52.68, returned $668,740 worth of Ordinary Shares to the company (8,589 units at $77.86), covered exercise/tax liability with 1,428 units of Ordinary Shares and sold $207,942 worth of Ordinary Shares (2,675 units at $77.74) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- SEC Form 3 filed by new insider Folli Stefano
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits